PL1651774T3 - Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami - Google Patents
Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynamiInfo
- Publication number
- PL1651774T3 PL1651774T3 PL04743565T PL04743565T PL1651774T3 PL 1651774 T3 PL1651774 T3 PL 1651774T3 PL 04743565 T PL04743565 T PL 04743565T PL 04743565 T PL04743565 T PL 04743565T PL 1651774 T3 PL1651774 T3 PL 1651774T3
- Authority
- PL
- Poland
- Prior art keywords
- statin
- polymorphisms
- pharmacokinetics
- humans
- effect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317592.4A GB0317592D0 (en) | 2003-07-26 | 2003-07-26 | Method |
| EP04743565A EP1651774B1 (en) | 2003-07-26 | 2004-07-26 | Use of polymorphisms in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy |
| PCT/GB2004/003236 WO2005012566A2 (en) | 2003-07-26 | 2004-07-26 | Use of polymorphisis in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1651774T3 true PL1651774T3 (pl) | 2007-12-31 |
Family
ID=27772801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04743565T PL1651774T3 (pl) | 2003-07-26 | 2004-07-26 | Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7700277B2 (enExample) |
| EP (1) | EP1651774B1 (enExample) |
| JP (1) | JP4166257B2 (enExample) |
| AT (1) | ATE373730T1 (enExample) |
| CY (1) | CY1107801T1 (enExample) |
| DE (1) | DE602004009083T2 (enExample) |
| DK (1) | DK1651774T3 (enExample) |
| ES (1) | ES2291899T3 (enExample) |
| GB (1) | GB0317592D0 (enExample) |
| PL (1) | PL1651774T3 (enExample) |
| PT (1) | PT1651774E (enExample) |
| WO (1) | WO2005012566A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1784504A2 (en) * | 2004-07-21 | 2007-05-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
| US20110112186A1 (en) * | 2008-02-29 | 2011-05-12 | Isis Innovation Limited | Diagnostic methods |
| US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
| US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
| EP3324184A1 (en) * | 2011-10-13 | 2018-05-23 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
| US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
| CA2968221A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
| US10572811B2 (en) * | 2015-01-29 | 2020-02-25 | Splunk Inc. | Methods and systems for determining probabilities of occurrence for events and determining anomalous events |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| CN110904215A (zh) * | 2019-12-16 | 2020-03-24 | 西安和合医学检验所有限公司 | 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32011A (en) * | 1861-04-09 | Coffee-pot | ||
| US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4902614A (en) * | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| GB8902689D0 (en) | 1989-02-07 | 1989-03-30 | Ici Plc | Assay method |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| ES2386007T3 (es) | 1993-11-12 | 2012-08-07 | Phri Properties, Inc. | Sonda de hibridación para la detección de ácido nucléico, tallos universales, métodos y kits |
| WO2000008157A2 (en) | 1998-08-07 | 2000-02-17 | Axys Pharmaceuticals, Inc. | Human anion transporter genes atnov |
| US20020090622A1 (en) | 2000-08-23 | 2002-07-11 | Monisola Adeokun | Chemical compounds |
-
2003
- 2003-07-26 GB GBGB0317592.4A patent/GB0317592D0/en not_active Ceased
-
2004
- 2004-07-26 JP JP2006521655A patent/JP4166257B2/ja not_active Expired - Fee Related
- 2004-07-26 WO PCT/GB2004/003236 patent/WO2005012566A2/en not_active Ceased
- 2004-07-26 ES ES04743565T patent/ES2291899T3/es not_active Expired - Lifetime
- 2004-07-26 US US10/566,054 patent/US7700277B2/en not_active Expired - Fee Related
- 2004-07-26 DE DE602004009083T patent/DE602004009083T2/de not_active Expired - Lifetime
- 2004-07-26 PL PL04743565T patent/PL1651774T3/pl unknown
- 2004-07-26 PT PT04743565T patent/PT1651774E/pt unknown
- 2004-07-26 EP EP04743565A patent/EP1651774B1/en not_active Expired - Lifetime
- 2004-07-26 AT AT04743565T patent/ATE373730T1/de active
- 2004-07-26 DK DK04743565T patent/DK1651774T3/da active
-
2007
- 2007-11-14 CY CY20071101470T patent/CY1107801T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1651774E (pt) | 2007-11-16 |
| ATE373730T1 (de) | 2007-10-15 |
| EP1651774B1 (en) | 2007-09-19 |
| US20070031838A1 (en) | 2007-02-08 |
| ES2291899T3 (es) | 2008-03-01 |
| GB0317592D0 (en) | 2003-08-27 |
| DE602004009083T2 (de) | 2008-06-19 |
| US7700277B2 (en) | 2010-04-20 |
| JP2007500005A (ja) | 2007-01-11 |
| EP1651774A2 (en) | 2006-05-03 |
| DE602004009083D1 (de) | 2007-10-31 |
| WO2005012566A2 (en) | 2005-02-10 |
| CY1107801T1 (el) | 2013-06-19 |
| DK1651774T3 (da) | 2008-01-07 |
| JP4166257B2 (ja) | 2008-10-15 |
| WO2005012566A3 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107801T1 (el) | Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης | |
| DE60310576D1 (en) | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| ATE428411T1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
| ATE353217T1 (de) | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren | |
| ATE506953T1 (de) | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel | |
| AU2002327180A1 (en) | Detection and therapy of vulnerable plaque with photodynamic compounds | |
| IL180872A0 (en) | Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv | |
| TW200518769A (en) | Use of calcitonin in osteoarthritis | |
| NO20040516L (no) | Kombinasjonsterapi for behandling av kreft. | |
| WO2005016883A3 (en) | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof | |
| IL180138A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
| ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
| WO2007047608A3 (en) | Fibrin targeted therapeutics | |
| WO2005013911A3 (en) | Protective and therapeutic uses for tocotrienols | |
| SE0301654D0 (sv) | Novel compounds | |
| NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
| TR201900241T4 (tr) | Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar. | |
| WO2005123113A3 (en) | Interferon compositions and methods of use thereof | |
| UA85187C2 (en) | 2-aminobenzoyl derivatives | |
| WO2005011611A3 (en) | Bicyclic compounds and compositions as pdf inhibitors | |
| NO20072048L (no) | Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer. | |
| ATE493390T1 (de) | 2,3-diaryl-pyrazolidine derivate als neurotensin abbauende enzyme-inhibitoren | |
| WO2005056054A3 (en) | METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB | |
| IL164356A0 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy |